10-Q/A: BioNexus Gene Lab Corp. Reports Third Quarter 2023 Results, Revenue Slightly Down, Operating Expenses Surge Due to Nasdaq Listing

BioNexus Gene Lab Corp. reports a slight decrease in revenue and a significant increase in operating expenses for the third quarter of 2023, primarily due to costs associated with its Nasdaq listing.

Summary

• BioNexus Gene Lab Corp. reported a revenue of $2,553,686 for the third quarter of 2023, a slight decrease of 0.8% compared to $2,575,086 in the same period of 2022.
• The company's cost of revenue decreased by 3.4% to $2,199,354 in Q3 2023 from $2,275,587 in Q3 2022.
• Gross profit increased by 18.3% to $354,332 in Q3 2023 from $299,499 in Q3 2022.
• Other income saw a significant increase of 268.3% to $199,284 in Q3 2023 from $54,110 in Q3 2022.
• Operating expenses surged by 635.9% to $3,082,128 in Q3 2023 from $418,824 in Q3 2022, primarily due to costs associated with the Nasdaq listing and a provision for losses on accounts receivable.
• The company reported a net loss of $2,609,189 for Q3 2023, a significant increase from the net loss of $77,401 in Q3 2022.
• For the nine months ended September 30, 2023, revenue was $7,497,739, a decrease of 7.3% compared to $8,089,132 in the same period of 2022.
• The net loss for the nine months ended September 30, 2023 was $2,937,506, compared to a net loss of $198,997 for the same period in 2022.
• The company completed a public offering on July 24, 2023, raising $5.75 million before expenses.
• A 12-for-1 reverse stock split was implemented on July 20, 2023.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with a significant increase in operating expenses and net loss, overshadowing the slight revenue decrease and successful Nasdaq listing. The company faces challenges in its core businesses and needs to improve its financial performance.

Positives

• Gross profit increased by 18.3% in Q3 2023 compared to Q3 2022.
• Other income saw a significant increase of 268.3% in Q3 2023.
• The company successfully completed a public offering and listed on the Nasdaq, raising $5.75 million before expenses.
• The company's working capital increased to $6,625,767 as of September 30, 2023, compared to $4,017,749 as of December 31, 2022.

Negatives

• Revenue decreased slightly by 0.8% in Q3 2023 compared to Q3 2022.
• Operating expenses increased dramatically by 635.9% in Q3 2023, primarily due to Nasdaq listing costs and a provision for losses on accounts receivable.
• The company's net loss significantly increased to $2,609,189 in Q3 2023 from $77,401 in Q3 2022.
• The company experienced a foreign currency loss of $18,603 in Q3 2023.
• MRNA Scientific-Malaysia's revenue decreased by 27.8% for the nine months ended September 30, 2023, compared to the same period in 2022.

Risks

• The company's RNA screening business has been adversely affected by the COVID-19 pandemic.
• The company faces competition in the industrial chemicals market, which has led to reduced selling prices.
• The company's operating expenses have increased significantly due to costs associated with becoming a public company.
• The company's future liquidity could be impacted by the addition of administrative and marketing personnel, website development, and increased advertising and marketing costs.
• The company's internal control over financial reporting has been identified as requiring further improvement.

Future Outlook

The company believes that cash flow from operations will be sufficient to sustain its current level of operations for at least the next 12 months. The company anticipates that the addition of administrative and marketing personnel, website development, and increased advertising and marketing costs could impact future liquidity.

Management Comments

• The results of operations of our subsidiary, MRNA Scientific-Malaysia, with respect to its RNA screening process have been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants.
• The results of operations for Chemrex were adversely impacted during fiscal year 2023 and the 1st quarter of 2023 as businesses of Chemrex customers especially the manufacturers had suffered significant impact.
• Management considers its internal control over financial reporting required further improvement.

Industry Context

The company operates in the biochemical industry, with a focus on molecular diagnostics and industrial chemicals. The RNA screening business has been impacted by the COVID-19 pandemic, while the industrial chemicals business has faced challenges due to supply chain disruptions and reduced demand. The company's Nasdaq listing is a significant step that could provide access to capital and increase visibility.

Comparison to Industry Standards

• The company's revenue decline of 7.3% for the nine months ended September 30, 2023, contrasts with some growth seen in the broader diagnostics industry, although specific comparisons are difficult without detailed competitor data.
• The significant increase in operating expenses due to the Nasdaq listing is not typical for all companies in the biochemical industry, but is a common occurrence for companies undergoing an IPO.
• The company's net loss of $2,937,506 for the nine months ended September 30, 2023, is a significant deviation from the industry average, which typically sees a mix of profitable and unprofitable companies depending on their stage of development and market position.
• The company's reliance on a single geographic region (Malaysia) for its operations exposes it to specific regional economic and health-related risks, unlike larger, more diversified competitors.
• The company's gross profit margin of 14.2% for the nine months ended September 30, 2023, is lower than the industry average, which is typically in the range of 30-50% for diagnostics companies, indicating potential pricing or cost management issues.

Management Changes

Corporate Governance

Legal Proceedings

• There are presently no pending legal proceedings to which the Company or any of its property is subject.

Stakeholder Impact

• Shareholders have experienced a significant increase in net loss and dilution due to the public offering and share issuances.
• Employees may be affected by the management changes and potential restructuring.
• Customers may be impacted by the company's financial performance and any changes in its business strategy.
• Suppliers may be affected by the company's financial performance and any changes in its purchasing patterns.
• Creditors may be concerned about the company's increased net loss and potential impact on its ability to repay debts.

Next Steps

• The company will continue to monitor the impact of the COVID-19 pandemic on its RNA screening business.
• The company will focus on improving its financial performance and managing its operating expenses.
• The company will work to address the identified material weaknesses in internal control over financial reporting.
• The company will actively identify a replacement personnel for the CFO position.

Key Dates

Keywords

Nasdaq listing, reverse stock split, public offering, RNA screening, industrial chemicals, operating expenses, net loss, revenue, financial results, Bionexus Gene Lab Corp